EPIQ Diagnostic Ultrasound System Series, Affiniti Diagnostic Ultrasound System Series, CX50 Diagnostic Ultrasound System, Sparq Diagnostic Ultrasound System, Lumify Diagnostic Ultrasound System

The Philips suite of diagnostic ultrasound systems (Lumify, EPIQ, Affiniti, CX50, Sparq) and the associated QLAB Advanced Quantification Software provide comprehensive ultrasound imaging and fluid flow analysis capabilities for numerous medical applications, utilizing a range of transducer technologies and imaging modes. The primary update involves an expansion of their user labeling to incorporate specific guidance for lung and cardiac ultrasound imaging in patients with COVID-19, leveraging existing device functionalities to address evolving clinical demands.

The Philips Lumify, EPIQ, Affiniti, CX50, and Sparq Diagnostic Ultrasound Systems are versatile, reusable medical devices designed for high-resolution diagnostic imaging and fluid flow analysis across a wide range of clinical applications, including general imaging, interventional radiology, cardiology, vascular assessments, and OB/GYN. These systems employ various compatible transducers (such as curved array, linear array, sector/phased array, and xMatrix technology) and operate by emitting and receiving ultrasound waves to generate images for interpretation by healthcare professionals in diverse settings, from hospitals and clinics to point-of-care locations. The systems support multiple imaging modes, and their hardware typically consists of a primary console with integrated software and a selection of transducers tailored for specific anatomical imaging. Complementing these imaging systems, the Philips QLAB Advanced Quantification Software is a software application package for viewing and quantifying image data acquired from Philips ultrasound systems, available as a standalone product or integrated into the systems. A significant update described for these devices is the expansion of their user labeling to include specific information and guidance on lung and cardiac ultrasound imaging for patients with coronavirus disease 2019 (COVID-19). This labeling expansion is based on established medical methodologies and current society guidelines, indicating an adaptation of these existing technologies to address emerging clinical needs in the context of the pandemic, without changes to the fundamental hardware or software of the devices themselves.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific lung and cardiac ultrasound imaging protocols, based on established methods or society guidelines, are detailed in the expanded labeling for COVID-19 patients across the Lumify, EPIQ, Affiniti, CX50, and Sparq systems?; How does the QLAB Advanced Quantification Software specifically aid in the analysis of lung and cardiac ultrasound images obtained from COVID-19 patients, and are there new quantification parameters relevant to this cohort?; Beyond the expanded COVID-19 labeling, what are the primary technological and clinical application differences that would lead a clinician to choose one Philips ultrasound system (e.g., EPIQ vs. Lumify vs. CX50) over another for general diagnostic purposes?; Could you elaborate on the functional benefits and imaging enhancements provided by the xMatrix transducer technology mentioned for some Philips ultrasound systems, particularly in complex anatomical sites or for volumetric imaging?; For the EPIQ and Affiniti systems, what are the workflow advantages and diagnostic improvements observed when integrating Philips EchoNavigator for image guidance in cardiovascular procedures that utilize both live X-ray and live Echo?